Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MGOL 1.05 + 305%
MGRX + 176% .70 rising ed and weight loss nice combo
ED to weight loss get hard then thin for the ladies a duo combo…lol
Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce the development of proprietary oral formulations of Semaglutide (“Slim”) and Tirzepatide (“Trim”) to aid in weight management. These innovative drugs, currently available predominantly in injectable form, have demonstrated remarkable efficacy in clinical trials. MangoRx’s new oral formulations are poised to revolutionize the weight loss market and capture significant market share.
The GLP-1 receptor agonists’ market, including both Semaglutide and Tirzepatide, is projected to reach over $164 billion in combined revenue by 2032, based on Visible Alpha consensus, ramping up from $37.9 billion in 2023. These are record-breaking revenues for any drug class in the history of drug development.
The oral formulations of Semaglutide and Tirzepatide are set to capture a significant share of this market, offering a convenient alternative to injections. Semaglutide, marketed under the brand names Ozempic® and Wegovy®, and Tirzepatide, marketed as Mounjaro® and Zepbound®, are both glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs have demonstrated impressive weight loss results in clinical trials. In a recent study, patients taking Semaglutide achieved an average weight loss of 15.2% over one year, while those taking Tirzepatide experienced an average weight loss of 15.7%. The oral formulations of Semaglutide and Tirzepatide are designed for daily consumption and are expected to provide similar weight loss benefits without the need for regular injections.
Patient preference studies consistently show a significant majority in favor of oral medications over injectables. This preference is anticipated to drive higher adoption rates and expand the existing market. The shift to an oral formulation offers a more accessible and convenient option for patients, potentially increasing adherence and overall treatment success.
“We are thrilled to introduce ‘Slim’ and ‘Trim’, MangoRx’s oral formulations of Semaglutide and Tirzepatide, to the weight loss market,” said Jacob Cohen, CEO and Co-Founder of MangoRx. “Our goal is to provide patients with a convenient and effective way to manage their weight and improve their overall health. We believe that these oral formulations have the potential to significantly impact the lives of millions of people worldwide.”
MangoRx plans to have the products available for customers on the company’s telemedicine platform in the beginning of the 3rd quarter with ‘Slim’ and ‘Trim’ competitively priced at $299/month and $399/month, respectively. MangoRx is committed to advancing the treatment of obesity and related conditions and is dedicated to improving the lives of patients worldwide.
Didn’t participate in earlier todays squeeze but 100,000 shares available only. Nice continuation
Going going gone again lol
FLJ + 50% BKKT AULT .46 … .50s will be back NVDA tomorrow and they printing Bitcoins regularly
MGOL taking the lead
0.5080
+0.2793
+122.13%
EDBL
Edible Garden
6.790
+2.990
+78.68%
AGRI
AgriFORCE Growing .
0.2153
+0.0867
+67.42%
MMAT
Meta Materials Inc
3.720
+1.420
+61.74%
BDRX
Biodexa Pharmaceut.
1.580
+0.310
+24.41%
MTC
MMTEC Inc
1.2900
+0.2400
+22.86%
CTNT
Cheetah Net Supply.
17.7300
+2.9700
+20.12%
LRMR
Larimar Therapeuti.
8.600
+1.330
+18.29%
SHLT
SHL Telemedicine A.
6.40
+0.98
+18.08%
TVGN
Tevogen Bio Holdin.
0.913
+0.133
+17.05%
EDBL 9.29 + 144% cash out some more on the way up
EDBL $8.50 + 123% time to cash out some shares
AGRI
0.2469
+0.1183
+91.99%
MMAT
Meta Materials Inc
3.900
+1.600
+69.57%
EDBL
Edible Garden
5.300
+1.500
+39.47%
MTC
MMTEC Inc
1.3800
+0.3300
+31.43%
LRMR
Larimar Therapeuti.
9.100
+1.830
+25.17%
MGOL
MGO Global Inc
0.274
+0.0453
+19.81%
MNDR
Mobilehealth Netwo.
2.18
+0.25
+12.95%
SING
SinglePoint Inc
0.3000
+0.0300
+11.11%
CRKN
Crown Electrokinet.
0.213
+0.014
+7.04%
CTNT
Cheetah Net Supply.
17.71
+2.9500
+19.99%
MMAT CTNT AGRI EDBL MTC LRMR CRKN ANY RIOT CLSK
MMAT
Meta Materials Inc
4.03
+1.730
+75.22%
CTNT
Cheetah Net Supply.
19.49
+4.7300
+32.05%
AGRI
AgriFORCE Growing .
0.2063
+0.0777
+60.42%
EDBL
Edible Garden
5.300
+1.500
+39.47%
MTC
MMTEC Inc
1.42
+0.3700
+35.24%
LRMR
Larimar Therapeuti.
9.100
+1.830
+25.17%
CRKN
Crown Electrokinet.
0.227
+0.028
+13.92%
ANY
Sphere 3D Corp
1.600
+0.070
+4.58%
RIOT
Riot Platforms
11.18
+0.22
+2.01%
CLSK
CleanSpark Inc
18.70
+0.39
+2.13
BKKT 5m float $13.47 right back at you lol. Anything Bitcoin !!! going 2 days before NVDA earnings report. Watch NVDA Wednesday for $950 breakout then $1000. The NVDA deal with META for LLAMA there chatbox AI version rolling out..
SAI BTM SLNH BTBT HUT ELWS MARA RIOT CAN HIVE BTCM BTDR BTCS
MATH CLSK WULF IREN ANY BITF ARBK HUT MIGI GREE BTBT MARA RIOT SOS SDIG COIN NUKK CGA OCTO CIFR LMFA BRRR
NKGN $1.71 so we good until $2s here covered lol..looks liken $1.50s should have been already wisely exercised based on trading float
4,721,533 shares of common stock that are issuable upon the exercise of warrants (the “Private Warrants”) originally issued in a private placement to Graf Acquisition Partners IV LLC (the “Sponsor”), at a price of $1.50 per warrant, in connection with the initial public offering of Graf Acquisition Corp. IV (“Graf”), with an exercise price of $11.50 per share, (ii) up to 3,432,286 shares of common stock that are issuable upon the exercise of certain warrants (the “Public Warrants”) originally issued as part of the units at a price of $10.00 per unit in the initial public offering of Graf, with an exercise price of 11.50 per share, (iii) up to 523,140 shares of common stock that are issuable upon the exercise of warrants issued to the Sponsor at a price of $1.50 per warrant, in connection with the conversion of working capital loans (the “Working Capital Warrants”), with an exercise price of $11.50 per share, (iv) up to 1,000,000 shares of common stock that are issuable upon the exercise of warrants (the “SPA Warrants”) at an exercise price of $11.50 per share, which were issued pursuant to the Securities Purchase Agreement (as defined below), (v) up to 10,209,994 shares of common stock issuable upon the exercise of the warrants (the “PIPE Warrants”) issued pursuant to those certain subscription agreements, dated September 26, 2023 and September 27, 2023 (collectively, the “Warrant Subscription Agreements”), with each such PIPE Warrant issued at $1.00 per warrant, with the exercise price initially set at $10.00, $12.50 and $15.00 per share for each of the three tranches, respectively, and such exercise price being reset to $2.00 per share for all tranches pursuant to those certain amended and restated warrants issued on April 25, 2024, (vi) up to 7,510,929 shares of common stock issuable upon exercise of (a) 400,000 warrants (the “Ling Warrants”) issued to Mary Ling together with the $400,000 aggregate principal amount and 20% premium at maturity short term bridge note (the “Ling Note”) dated February 7, 2024, as amended and restated on April 12, 2024, for an aggregate purchase price of $400,000, which have an exercise price of $2.00 per share, (b) 122,000 warrants (the “AB Warrants”) issued together with the $100,000 principal amount and 24.64% premium at maturity AB Note (as defined below) for an aggregate purchase price of $100,000, which have an exercise price of $2.00 per share, (c) 750,000 warrants (the “Clearview Warrants”) issued together with the $220,000 aggregate principal amount and 20% premium at maturity Clearview Notes (as defined below) for an aggregate purchase price of $200,000, which have an exercise price of $1.50 per share, (d) 330,000 warrants (the “FirstFire Warrants”) issued pursuant to the FirstFire SPA (as defined below) together with a $330,000 principal amount 12% unsecured promissory note for an aggregate purchase price of $300,000, which have an exercise price of $2.00 per share, (e) 880,000 warrants (the “Meteora Warrants”) issued pursuant to the Meteora SPAs (as defined below) together with the Meteora Notes (as defined below) for an aggregate purchase price of $500,000, which have an exercise price of $2.00 per share, (f) 440,000 warrants (the “Sandia Warrants”) issued pursuant to the Sandia SPA (as defined below) together with the Sandia Note (as defined below) for an aggregate purchase price of $200,000, which have an exercise price of $2.00 per share, (g) up to 1,650,000 warrants (the “AJB Warrants”) issuable pursuant to the AJB SPAs (as defined below) together with a $330,000 principal amount 12% unsecured promissory note and the AJB Notes (as defined below) for an aggregate purchase price $1,500,000, which have an exercise price of $2.00 per share, (h) 165,000 warrants (the “Kuwana Warrants”) issued pursuant to the Kuwana SPA (as defined below) together with the Kuwana Note (as defined below) for an aggregate purchase price of $150,000, which have an exercise price of $2.00 per share, (i) 133,929 warrants (the “Clearview Convertible Note Warrants”) issued pursuant to the Clearview SPA (as defined below) together with the Clearview Convertible Note (as defined below) for an aggregate purchase price of $121,175.32, which have an exercise price of $2.00 per share, (j) 440,000 warrants (the “Ling Convertible Note Warrants”) issued pursuant to the Ling SPA (as defined below) together with the Ling Convertible Note (as defined below) for an aggregate purchase price of $400,000, which have an exercise price of $2.00 per share, and (k) up to 2,200,000 warrants (the “Alpha Warrants” and together with the Ling Warrants, AB Warrants, Clearview Warrants, FirstFire Warrants, Meteora Warrants, Sandia Warrants, AJB Warrants, Kuwana Warrants, Clearview Convertible Note Warrants and Ling Convertible Note Warrants, the “Unsecured Convertible Note Warrants”) issuable pursuant to the Alpha SPA (as defined
Table of Contents
below) together with the Alpha Notes for an aggregate purchase price of $2,000,000, which have an exercise price of $2.00 per share, and (vii) up to 1,000,000 shares of common stock issuable upon exercise of warrants (the “BDW Warrants” and, together with the Private Warrants, Public Warrants, Working Capital Warrants, SPA Warrants, PIPE Warrants and Unsecured Convertible Notes Warrants, the “Warrants”) issued pursuant to the Equity and Business Loan Agreement (as defined below) together with the BDW Secured Note (as defined below) for an aggregate purchase price of $5,000,000, which have an exercise price of $2.00 per share.
This prospectus also relates to the issuance and sale by us of an aggregate of up to 6,852,693 shares of our common stock issuable upon conversion of notes, which consists of (i) up to 1,320,000 shares common stock that are issuable upon the conversion of the $10,000,000 aggregate principal amount of 5.0% / 8.0% Convertible Senior Notes due 2027 (the “Senior Convertible Notes”), which have a conversion price of $10.00 per share, that were issued in a private placement pursuant to the securities purchase agreement dated September 15, 2023 (the “Securities Purchase Agreement”), together with the 1,000,000 SPA Warrants, for an aggregate purchase price of $10.0 million, (ii) up to 2,828,520 shares of common stock issuable upon conversion of (a) $100,000 aggregate principal amount and 24.64% premium at maturity AB Note (as defined below), which has a conversion price of $2.00 per share, which outstanding balance is convertible into 12,320 shares of common stock, issued together with the AB Warrants for an aggregate purchase price of $100,000, (b) $550,000 aggregate principal amount of the 12% unsecured promissory notes entered into pursuant to the Meteora SPAs (as defined below) (the “Meteora Notes”), which have a conversion price of $2.00 per share, convertible into 308,000 shares of common stock, issued together with the Meteora Warrants for an aggregate purchase price of $500,000, (c) $220,000 principal amount of the 12% unsecured promissory note entered into pursuant to the Sandia SPA (as defined below) (the “Sandia Note”), which has a conversion price of $2.00 per share, convertible into 123,200 shares of common stock, issued together with the Sandia Warrants for an aggregate purchase price of $200,000, (d) up to $1,478,400 aggregate principal amount of the zero coupon notes issuable into pursuant to the AJB SPAs (as defined below) (the “AJB Notes”), which have a conversion price of $2.00 per share, convertible into 739,200 shares of common stock, issued together with the AJB Warrants for an aggregate purchase price of $1,500,000, (e) $165,000 aggregate principal amount of the 12% unsecured promissory note entered into pursuant to the Kuwana SPA (as defined below) (the “Kuwana Note”), which has a conversion price of $2.00 per share, convertible into 92,400 shares of common stock, issued together with the Kuwana Warrants for an aggregate purchase price of $150,000, (f) $133,928.57 aggregate principal amount of the 12% unsecured promissory note entered into pursuant to the Clearview SPA (as defined below) (the “Clearview Convertible Note”), which has a conversion price of $2.00 per share, convertible into 75,000 shares of common stock, issued together with the Clearview Convertible Note Warrants for an aggregate purchase price of $121,753.25, (g) $440,000 aggregate principal amount of the 12% unsecure promissory note entered into pursuant to the Ling SPA (as defined below) (the “Ling Convertible Note”), which has a conversion price of $2.00 per share, convertible into 246,400 shares of common stock, issued together with the Ling Convertible Note Warrants for an aggregate purchase price of $400,000, and (h) up to $2,464,000 aggregate principal amount of zero coupon notes issuable pursuant to the Alpha SPA (as defined below) (the “Alpha Notes” and together with the AB Note, Meteora Note, Sandia Note, AJB Note, Kuwana Note, Clearview Convertible Note and Ling Convertible Notes, the “Unsecured Convertible Notes”), which have a conversion price of $2.00 per share, convertible into up to 1,232,000 shares of common stock, issuable together with the Alpha Warrants for an aggregate purchase price of up to $2,000,000, and (iii) up to 2,704,173 shares of common stock that are issuable upon conversion of the $5,000,000 aggregate principal amount of the note entered into pursuant to the Equity and Business Loan Agreement (as defined below) (the “BDW Secured Note” and, together with the Senior Convertible Notes and Unsecured Convertible Notes, the “Convertible Notes”), which has a conversion price of $2.00 per share, issued together with the BDW Warrants for an aggregate purchase price of $5,000,000.
This prospectus also relates to the offer, sale or other disposition from time to time by the selling securityholders named in this prospectus or their permitted transferees (the “selling securityholders”) of up to 58,851,972 shares of common stock consisting of (i) up to 17,241,208 shares of common stock (excluding the shares of common stock underlying the Private Warrants and the Working Capital Warrants) pursuant to the Amended and Restated Registration Rights Agreement (as defined below), consisting of (a) up to 14,724,464 shares of common stock issued or issuable in connection with the Business Combination (as defined below) at an equity consideration value of approximately $10.00 per share by certain of the selling securityholders named in this prospectus and (b) up to 2,516,744 shares of common stock originally purchased by Graf Acquisition Partners LLC (the “Founder Shares”) in a private placement prior to Graf’s initial public offering, at an effective price of approximately $0.006 per share; (ii) up to 1,320,000 shares common stock (the “Convertible Notes Shares”) underlying the Senior Convertible Notes; (iii) up to 1,000,000 shares of common stock (the “SPA Warrant Shares”) underlying the SPA Warrants; (iv) up to 10,209,994 shares of common stock (the “PIPE Warrant Shares”) underlying the PIPE Warrants,
Table of Contents
(v) up to 1,080,000 shares of common stock (the “Polar FPA Shares”) issued at approximately $10.44 per share (excluding 80,000 shares of common stock of which were issued for no cash consideration but in consideration for the selling securityholder’s entering into the forward purchase arrangement with the Company), pursuant to the forward purchase agreement funding amount subscription agreement dated September 29, 2023 (the “Polar FPA Funding Subscription Agreement”), (vi) up to 4,721,533 shares of common stock (the “Private Warrant Shares”) underlying the Private Warrants; (vii) up to 523,140 shares of common stock (the “Working Capital Warrant Shares”) underlying the Working Capital Warrants; (viii) up to 4,750,463 shares of common stock that are issued as consideration shares under (a) certain short term bridge notes consisting of (A) 16,667 shares of common stock issued to Andrew Bail as consideration for his entry into the short term bridge note dated February 20, 2024, as amended and restated on April 19, 2024 (the “AB Note”) and (B) 7,334 shares of common stock issued to Clearview Ventures LLC (“Clearview”) as consideration for its entry into the short term bridge notes dated February 27, 2024 and March 7, 2024 (together, the “Clearview Notes”) and (b) certain securities purchase agreements consisting of (A) 250,000 shares of common stock issued to FirstFire Global Opportunities Fund, LLC (“FirstFire”) as consideration for its entry into the securities purchase agreement dated March 21, 2024 (the “FirstFire SPA”), (B) 666,667 shares of common stock issued to Meteora Entities as consideration for its entry into (1) the securities purchase agreement dated March 26, 2024 and letter agreement dated April 28, 2024 (the “First Meteora SPA”) and (2) the securities purchase agreement dated May 7, 2024 (the “Second Meteora SPA” and together with the First Meteora SPA, the “Meteora SPAs”), (C) 333,334 shares of common stock issued to Sandia Investment Management LP (“Sandia”) as consideration for its entry into the securities purchase agreement dated April 1, 2024 and letter agreement dated April 28, 2024 (the “Sandia SPA”) and (D) up to 1,250,000 shares of common stock issuable to AJB Capital Investments LLC (“AJB”) as consideration for its entry into (1) the securities purchase agreement dated April 1, 2024 (the “First AJB SPA”) and (2) the securities purchase agreement dated May 9, 2024 (the “Second AJB SPA” and together with the First AJB SPA, the “AJB SPAs”), (E) 125,000 shares of common stock issued to Eric Kuwana (“Kuwana”) as consideration for his entry into the securities purchase agreement dated April 30, 2024 (the “Kuwana SPA”) and (F) 101,461 shares of common stock issued to Clearview as consideration for its entry into the securities purchase agreement dated May 1, 2024 (the “Clearview SPA”), (G) 333,333 shares of common stock issued to Mary Ling (“Ling”) as consideration for her entry into the securities purchase agreement dated May 6, 2024 (the “Ling SPA”), and (H) up to 1,666,667 shares of common stock issuable to Generating Alpha Ltd. (“Alpha”) as consideration for its entry into the securities purchase agreement dated May 7, 2024, as amended on May 13, 2024 (the “Alpha SPA” and together with the AB Note, Clearview Notes, FirstFire SPA, Meteora SPA, Sandia SPA, AJB SPA, Kuwana SPA, Clearview SPA and Ling SPA, the “Unsecured Notes Agreements”); (ix) up to 2,828,520 shares of common stock underlying the Unsecured Convertible Notes; (x) up to 7,510,929 shares of common stock underlying the Unsecured Convertible Note Warrants; (xi) up to 1,167,990 shares of common stock (the “Meteora FPA Shares”) issuable to Meteora Entities pursuant to the Forward Purchase Agreements (as defined below); (xii) up to 248,360 shares of common stock (the “Sandia FPA Shares”) issued to Sandia pursuant to the Forward Purchase Agreements (as defined below); and (xiii) up to 6,249,835 shares of common stock issuable pursuant to that certain Equity and Business Loan Agreement, dated April 5, 2024 (the “Equity and Business Loan Agreement”), by and among NKGen (as defined below), Legacy NKGen (as defined below) and BDW Investment LLC (“BDW”) consisting of (a) 2,545,662 shares of common stock issuable as consideration for BDW’s entry into the Equity and Business Loan Agreement, (b) 2,704,173 shares of common stock underlying the BDW Secured Note and (c) 1,000,000 shares of common stock underlying the BDW Warrants. We will not receive any proceeds from the sale of shares of common stock by the selling securityholders pursuant to this prospectus.
The selling securityholders may offer, sell or distribute all or a portion of the securities hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any of the proceeds from such sales of these securities, except with respect to amounts received by us upon exercise of the Warrants for cash. We believe the likelihood that warrant holders will exercise their Warrants for cash and therefore the amount of cash proceeds that we would receive, is dependent upon the trading price of our common stock. The market price of our common stock is lower than the exercise prices of the Warrants as of the date of this prospectus. The value of our common stock will fluctuate and may not align with the exercise price of the Warrants at any given time. If the trading price for our common stock is less than the exercise price of the Warrants, meaning the Warrants are “out of the money”, we believe the holders of Warrants will be unlikely to exercise these Warrants. In addition, the Warrants, may be exercised on a cashless basis, under certain circumstances described herein. To the extent such Warrants are exercised on a cashless basis, we would not receive any cash from such exercise and the total amount of cash that we would receive from the exercise of the Warrants will decrease. Such exercises may not bring us more liquidity but result in further dilution of our common stock, which could adversely affect our financial
Table of Contents
position. In addition, we may not have sufficient cash to fund on our ongoing operations, and the lack of liquidity could negatively impact our cash flow and business. See “Risk Factors — Risks Related to Our Business and Industry — We currently do not have sufficient funds to service our operations and accrued expenses and payables and require additional capital. Our independent registered public accountants and management have expressed substantial doubt as to our ability to continue as a going concern without additional capital” for more details. The Public Warrants and the PIPE Warrants may only be exercised for cash provided there is then an effective registration statement registering the shares of common stock issuable upon the exercise of such warrants. If there is not a then-effective registration statement, then such warrants may be exercised on a “cashless basis,” pursuant to an available exemption from registration under the Securities Act of 1933, as amended. We will bear all costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or “blue sky” laws. The selling securityholders will bear all commissions and discounts, if any, attributable to their sale of shares of common stock or Warrants. See the section titled “Plan of Distribution.”
Our common stock is listed on The Nasdaq Global Market under the symbol “NKGN” and our Public Warrants are listed on The Nasdaq Capital Market under the symbol “NKGNW”. On May 12, 2024, the last reported sales price of our common stock was $1.26 per share and the last reported sales price of our Public Warrants was $0.05 per warrant.
The number of shares of common stock being offered for resale in this prospectus (the “Resale Securities”) exceeds the number of shares of common stock constituting our public float. The Resale Securities represent approximately 367% of our public float and approximately 236% of our outstanding shares of common stock upon exercise of the Warrants and upon conversion of the Convertible Notes based on the trading price of our common stock on May 12, 2024. The sale of the Resale Securities, or the perception that these sales could occur, could depress the market price of our common stock. Despite a decline in price, our selling securityholders may still experience a positive rate of return on the shares purchased by them due to the lower price per share at which such shares were purchased. While these selling securityholders may, on average, experience a positive rate of return based on the current market price, public securityholders may not experience a similar rate of return on the common stock they purchased if there is such a decline in price and due to differences in the purchase price and the current market price. For example, based on the closing price of our common stock of $1.26 as of May 12, 2024, the holders of the Founder Shares, which were initially purchased at less than $0.01 per share prior to the initial public offering of Graf, would experience a potential profit of up to approximately $1.25 per share, or up to approximately $3.1 million in the aggregate for selling the 2,516,744 Founder Shares held by the Sponsor and Graf’s directors and are covered by this prospectus, assuming all Founder Shares held by the Sponsor that are subject to vesting and forfeiture are fully vested. However, the sales of the securities by the selling securityholders, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future and at a price that we deem appropriate.
We are an “emerging growth company” as defined under U.S. federal securities laws and, as such, have elected to comply with reduced public company reporting requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company.
Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 9 of this prospectus, and under similar headings in any amendments or supplements to this prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
Prospectus dated , 2024
NKGN 1.72 +51% next resistance needs to break is 2.32 looks doable then 2.71-3.77 is up next. If by any chance gets a solid break of 3.77 could see some resistance come in at play at 4.48-4.88
MMV $2.05..2.04 is resistance then 2.11-2.18 solid break of 2.18 should see 2.66-2.92
$HIMS $19.05 + 30% and HERS $24 is the resistance target if it holds $18.04 ..
Hims & Hers unlocks access to injectable GLP-1 medications, expanding its holistic weight loss program focused on personalized and affordable solutions; prices start as low as $199 a month
SAN FRANCISCO--(BUSINESS WIRE)--May 20, 2024--Hims & Hers Health, Inc., the leading health and wellness platform, today announced the addition of GLP-1 injections to its comprehensive weight loss portfolio, giving customers an affordable way to consistently access safe, high-quality weight loss treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240520817107/en/
Hims & Hers unlocks access to injectable GLP-1 medications, expanding its holistic weight loss program focused on personalized and affordable solutions; prices start as low as $199 a month. (Photo: Business Wire)
The company now offers access to GLP-1 injections in addition to weight management oral medication kits, so that customers can truly personalize their weight loss experience. Providing access to compounded GLP-1s means eligible customers can use medications with the same active ingredient as Ozempic® and Wegovy® without navigating the shortages and costs that are currently limiting access to the branded medications. Through a partnership with a leading US manufacturer of generic and 503B compounded injectable medications, Hims & Hers can help millions of Americans who have obesity and are looking for help safely managing their weight.
“The core of our business is to offer a truly personalized experience that customers can trust and rely on,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “We’ve leveraged our size and scale to secure access to one of the highest-quality supplies of compounded GLP-1 injections available today. We’re passing that access and value along to our customers, who deserve the highest standard of clinical safety and efficacy to meet their goals, and we're doing it in a safe, affordable way that others can’t deliver."
According to the US Food and Drug Administration (FDA), around 70% of American adults have obesity or are overweight, and losing 5 to 10% of that body weight can reduce weight-related health risks, such as diabetes and cardiovascular disease. GLP-1 medications can support healthy weight loss along with a reduced calorie diet and increased exercise by helping manage blood sugar levels, curb cravings and suppress appetite, so people eat less without feeling deprived.
The Hims & Hers platform is built on the belief that there is no one-size-fits-all approach to health and wellness treatments. Medical providers need a broad spectrum of solutions to address the needs of customers and that includes those with weight challenges. The current Hims & Hers Weight Loss offering is tracking to eclipse $100M in revenue by the end of 20251, as previously discussed, growing faster than any speciality in the company’s history. Building on that success, offering access to compounded GLP-1s gives medical providers and customers consistent and affordable access to effective, trusted and safe medications.
“We know weight loss medications alone do not treat obesity effectively, so we’ve built a holistic weight management solution that supports customers as they combine powerful medications with healthy lifestyle habits, such as exercise, improved sleep, and eating nutritious foods,” said Dr. Patrick Carroll, Chief Medical Officer of Hims & Hers. “Our comprehensive approach to weight loss comes with support from medical providers who understand the nuance of weight gain and weight loss. We design all of our solutions to help customers be successful in the long term, and that means providing an experience personalized to the individual.”
GLP-1 injections are fulfilled and shipped from Hims & Hers' affiliated pharmacies. Once consistent supply is available through the pharmacies' wholesaler, Hims & Hers plans to make branded options available to customers, expanding the offering beyond the current oral medication kits and compounded GLP-1 injectable medications.
For more information, visit https://www.forhers.com/weight-loss or https://www.hims.com/weight-loss.
Children’s $PLCE $14.49 + 20% tiny 400k float also
EDBL $3.97 + 10% new 400 k float could go
OPGN BSFC keep on radar reverse split today
GTBP 8.33 going for next zone out of all shares now e even further up should reach is 7.56-8.04 only 100,000 shares tradeable for retail squeeze and MM club is squeezing
GTBP 7.33 me personally 90% out now enjoy the rest of your morning
GTBP 7.31 .. a zone even further up should reach is 7.56-8.04 only 100,000 shares tradeable for retail squeeze and MM club is squeezing
KTRA .21 + 40% close .14 ..I see you sneaking up .. a solid break of .21 and then .29 comes
GTBP 7.12 ..7.05 broken ..solid break of 7.05 the. a zone even further up should reach is 7.56-8.04 only 100,000 shares tradeable for retail squeeze ..MM thanks again for DD
GTBP 6.48….. play of the early morning thanks MM. next zone is 6.33 to 7.05 which is a step up from previous RS split price
GTBP 6.24 let’s see a solid break of 6.33 to upper end of zone 7.05
..play of the early morning thanks MM. next zone is 6.33 to 7.05 which is a step from previous RS split price
TANH .70 to $1.10 from .38 last week insider buying catalyst
FFIE
Faraday Future Int.
1.87
+0.8400
+81.55%
TANH
Tantech Holdings L.
1.14
+0.4830
+73.52%
SISI
Shineco Inc
1.25
+0.260
+26.25%
KTRA
Kintara Therapeuti.
0.178
+0.0350
+24.48%
DYN
Dyne
34.80
+7.12
+25.72%
SINT
SINTX Technologies
0.106
+0.0210
+24.71%
CRKN
Crown Electrokinet.
0.216
+0.045
+26.49%
AGRI
AgriFORCE Growing .
0.1242
+0.0209
+20.23%
Insider buying and boom .70 to $1
GTBP 7.05 here she goes .. GTBP 5.34 play of the early morning thanks MM. next zone is 6.33 to 7.05 which is a step @up from previous RS split price
GTBP 6.05 a zone even further up should reach is 7.56-8.04 only 100,000 shares tradeable for retail squeeze MM
GTBP 5.34 play of the early morning thanks MM. next zone is 6.33 to 7.05 which is a step from previous RS split price
GTBP $4.76 Moon man summary 90% institutional ownership by Girozentrale on 1m float leaves 100,000 shares for retail to pump. June catalyst upcoming
Price
MMV
MultiMetaVerse Hol.
1.28
+0.6600
+106.45%
FFIE
Faraday Future Int.
1.80
+0.7700
+74.76%
GTBP
GT Biopharma Inc
4.760
+1.640
+52.56%
SISI
Shineco Inc
1.35
+0.360
+36.35%
HLTH
Cue Health Inc
0.1337
+0.0373
+38.69%
CRKN
Crown Electrokinet.
0.215
+0.044
+25.73%
PEGY
Pineapple Holdings
0.1256
+0.0202
+19.17%
CPHI
China Pharma
0.3752
+0.0572
+17.99%
SINT
SINTX Technologies
0.1008
+0.0158
+18.59%
DRRX
Durect Corporation
1.0800
+0.1500
+16.13%
Moon man summary 90% institutional ownership by Girozentrale on 1m float leaves 100,000 shares for retail to pump. June catalyst
MMV
MultiMetaVerse Hol.
1.24
+0.6200
+100.00%
FFIE
Faraday Future Int.
1.73
+0.7000
+67.96%
CRKN
Crown Electrokinet.
0.255
+0.084
+49.01%
SINT
SINTX Technologies
0.1165
+0.0315
+37.06%
SISI
Shineco Inc
1.27
+0.280
+28.27%
GTBP
GT Biopharma Inc
3.940
+0.820
+26.28%
PEGY
Pineapple Holdings
0.1467
+0.0413
+39.18%
CPHI
China Pharma
0.3900
+0.0720
+22.64%
KWE
Kwesst Micro Syste.
0.4109
+0.0709
+20.85%
GWAV
Greenwave Tech Sol.
0.1802
+0.0261
+16.94%
All time record high sale of US treasuries by China in first quarter of 2024 means the World economy ready for toilet time soon enough
China selling billions in US treasuries means inflation and rates going down quicker then expected
ARQQ .44 JFBR .65 + 105% scalp those profits quickly dont look back ARQQ .43 + 10% watch beat down quantum plays next
JFBR .53 400k float +70%
RNAZ 1.32
HKD TOP the Hong Kong gang ready IFBD churn enough yet